Real-World Persistence Data Emerge for IL-23 Biologics in Plaque Psoriasis

Dermatology Times has published a new report on real-world persistence data for IL-23 biologic therapies in plaque psoriasis, adding an evidence layer that randomized controlled trials cannot supply: how long patients actually stay on these drugs once they leave the protocol and enter everyday practice.

The report sits at the intersection of two pressures dermatologists know well. IL-23 inhibitors — a class that has reshaped moderate-to-severe plaque psoriasis management in recent years — arrive with strong registrational efficacy data, yet persistence, the measure of whether patients refill and remain on therapy over months and years, is the metric that determines whether trial PASI results translate into durable disease control in the clinic.

Why persistence matters more than headline efficacy

Pivotal trials measure outcomes over tightly controlled windows, typically 12 to 16 weeks for the primary endpoint, with protocol-mandated visits and adherence support. Real-world persistence strips all of that away. Patients miss appointments, insurers intervene, injection-site reactions or waning response erode motivation, and the therapy gets switched or abandoned.

So when a publication of this kind reports on how IL-23 agents perform on that unguarded stage, the practical question for prescribers is straightforward: what does this change for drug selection at the point of care? A biologic with high week-16 PASI 90 rates but poor 12-month persistence can deliver worse long-term outcomes than a slightly slower agent patients actually stay on.

What the IL-23 class brings to the question

The IL-23 inhibitors — targeting the p19 subunit of interleukin-23 — entered psoriasis care with a dosing profile dermatologists quickly noticed: maintenance intervals that stretch to every eight or twelve weeks depending on the agent. That cadence matters for persistence. Fewer injections mean fewer clinic touches, fewer copay events per year, and fewer opportunities for a patient to drift off therapy.

Real-world datasets, typically drawn from pharmacy claims, registry programs, or electronic health record networks, are the standard instrument for measuring this. They capture discontinuation rates, time-to-discontinuation, and switching patterns across thousands of patients — a scale and follow-up duration no registrational trial matches.

The Dermatology Times report contributes to a growing body of such evidence for the IL-23 class, and Derm Field readers tracking comparative biologics data will recognize the pattern: class-level and agent-level persistence figures have become a routine part of formulary discussions and payer negotiations, alongside efficacy and safety.

What does this change for practice?

For clinicians, persistence data feeds three concrete decisions. First, drug selection in treatment-naïve patients, where a durable agent reduces the churn of switching. Second, payer conversations, where real-world discontinuation rates increasingly appear in prior authorization criteria. Third, shared decision-making, where a patient told they will inject eight or fewer times a year often weighs that against efficacy claims on the spot.

The caveat is the usual one for observational data: persistence is a proxy, confounded by insurance design, patient population, and the fact that patients who stop a drug for any reason — access, cost, remission — count identically in the denominator. The strongest studies separate discontinuation due to adverse events from discontinuation due to loss of efficacy or non-clinical causes, and that granularity is what elevates a persistence report from background noise to actionable evidence.

Dermatology Times' decision to foreground this dataset signals where the field is heading: as more IL-23 agents and biosimilars crowd the psoriasis market, real-world durability — not just week-16 trial scores — will increasingly decide which biologics dermatologists reach for first.